TLSA - Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients | Benzinga
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) has taken a major step towards addressing Secondary Progressive Multiple Sclerosis (SPMS) by initiating Phase 2a clinical trials for its intranasal foralumab program. The company recently hosted an Investigator's Meeting in collaboration with principal investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham Healthcare System, to commence site initiation for this pivotal research.
Key Highlights:
- Tiziana Life Sciences is advancing its lead intranasal foralumab program into Phase 2a clinical testing, specifically targeting non-active ...